Exhaled Breath Analysis of Lung Cancer Patients Using Metal Oxide Sensor

2011 ◽  
Author(s):  
Joon-Boo Yu ◽  
Jeong-Ok Lim ◽  
Hyung-Gi Byun ◽  
Jeung-Soo Huh
Keyword(s):  
Lung Cancer ◽  
Metal Oxide ◽  
Cancer Patients ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Exhaled Breath Analysis ◽  
Metal Oxide Sensor

scholarly journals Exhaled Breath Analysis of Lung Cancer Patients Using a Metal Oxide Sensor

2011 ◽  
Vol 20 (5) ◽  
pp. 300-304 ◽  
Author(s):  
Joon-Boo Yu ◽  
Hyung-Gi Byun ◽  
Sholin Zhang ◽  
Seoung-Hun Do ◽  
Jeong-Ok Lim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Metal Oxide ◽  
Cancer Patients ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Exhaled Breath Analysis ◽  
Metal Oxide Sensor

scholarly journals VOC biomarkers identification and predictive model construction for lung cancer based on exhaled breath analysis: research protocol for an exploratory study

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e028448 ◽  
Author(s):  
Wenwen Li ◽  
Wei Dai ◽  
Mingxin Liu ◽  
Yijing Long ◽  
Chunyan Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Predictive Model ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Solid Phase ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Exhaled Breath Analysis

IntroductionLung cancer is the most common cancer and the leading cause of cancer death in China, as well as in the world. Late diagnosis is the main obstacle to improving survival. Currently, early detection methods for lung cancer have many limitations, for example, low specificity, risk of radiation exposure and overdiagnosis. Exhaled breath analysis is one of the most promising non-invasive techniques for early detection of lung cancer. The aim of this study is to identify volatile organic compound (VOC) biomarkers in lung cancer and to construct a predictive model for lung cancer based on exhaled breath analysis.Methods and analysisThe study will recruit 389 lung cancer patients in one cancer centre and 389 healthy subjects in two lung cancer screening centres. Bio-VOC breath sampler and Tedlar bag will be used to collect breath samples. Gas chromatography-mass spectrometry coupled with solid phase microextraction technique will be used to analyse VOCs in exhaled breath. VOC biomarkers with statistical significance and showing abilities to discriminate lung cancer patients from healthy subjects will be selected for the construction of predictive model for lung cancer.Ethics and disseminationThe study was approved by the Ethics Committee of Sichuan Cancer Hospital on 6 April 2017 (No. SCCHEC-02-2017-011). The results of this study will be disseminated in presentations at academic conferences, publications in peer-reviewed journals and the news media.Trial registration numberChiCTR-DOD-17011134; Pre-results.

Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis

2014 ◽  
Vol 67 (8) ◽  
pp. 707-711 ◽  
Author(s):  
A Jasmijn Hubers ◽  
Paul Brinkman ◽  
Remco J Boksem ◽  
Robert J Rhodius ◽  
Birgit I Witte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Dna Hypermethylation ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Exhaled Breath Analysis ◽  
Validation Set

AimsThe aim of this study is to explore DNA hypermethylation analysis in sputum and exhaled breath analysis for their complementary, non-invasive diagnostic capacity in lung cancer.MethodsSputum samples and exhaled breath were prospectively collected from 20 lung cancer patients and 31 COPD controls (Set 1). An additional 18 lung cancer patients and 8 controls only collected exhaled breath as validation set (Set 2). DNA hypermethylation of biomarkers RASSF1A, cytoglobin, APC, FAM19A4, PHACTR3, 3OST2 and PRDM14 was considered, and breathprints from exhaled breath samples were created using an electronic nose (eNose).ResultsBoth DNA hypermethylation markers in sputum and eNose were independently able to distinguish lung cancer patients from controls. The combination of RASSF1A and 3OST2 hypermethylation had a sensitivity of 85% with a specificity of 74%. eNose had a sensitivity of 80% with a specificity of 48%. Sensitivity for lung cancer diagnosis increased to 100%, when RASSF1A hypermethylation was combined with eNose, with specificity of 42%. Both methods showed to be complementary to each other (p≤0.011). eNose results were reproducible in Set 2.ConclusionsWhen used in concert, RASSF1A hypermethylation in sputum and exhaled breath analysis are complementary for lung cancer diagnosis, with 100% sensitivity in this series. This finding should be further validated.

Cancerous glucose metabolism in lung cancer—evidence from exhaled breath analysis

2016 ◽  
Vol 10 (2) ◽  
pp. 026012 ◽  
Author(s):  
Tali Feinberg ◽  
Layah Alkoby-Meshulam ◽  
Jens Herbig ◽  
John C Cancilla ◽  
Jose S Torrecilla ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Glucose Metabolism ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Exhaled Breath Analysis

Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link?

Lung Cancer ◽  
2010 ◽  
Vol 67 (1) ◽  
pp. 108-113 ◽  
Author(s):  
Giovanna E. Carpagnano ◽  
Antonio Spanevello ◽  
Grazia P. Palladino ◽  
Claudia Gramiccioni ◽  
Cinzia Ruggieri ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cigarette Smoke ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Cox 2 ◽  
Breath Condensate

scholarly journals MOS Sensors Array for the Discrimination of Lung Cancer and At-Risk Subjects with Exhaled Breath Analysis

Chemosensors ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 209
Author(s):  
Davide Marzorati ◽  
Luca Mainardi ◽  
Giulia Sedda ◽  
Roberto Gasparri ◽  
Lorenzo Spaggiari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Survival Rate ◽  
Mortality Rate ◽  
Early Diagnosis ◽  
Gas Sensor ◽  
Electronic Nose ◽  
Gas Sensors ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Exhaled Breath Analysis

Lung cancer is characterized by a tremendously high mortality rate and a low 5-year survival rate when diagnosed at a late stage. Early diagnosis of lung cancer drastically reduces its mortality rate and improves survival. Exhaled breath analysis could offer a tool to clinicians to improve the ability to detect lung cancer at an early stage, thus leading to a reduction in the associated survival rate. In this paper, we present an electronic nose for the automatic analysis of exhaled breath. A total of five a-specific gas sensors were embedded in the electronic nose, making it sensitive to different volatile organic compounds (VOCs) contained in exhaled breath. Nine features were extracted from each gas sensor response to exhaled breath, identifying the subject breathprint. We tested the electronic nose on a cohort of 80 subjects, equally split between lung cancer and at-risk control subjects. Including gas sensor features and clinical features in a classification model, recall, precision, and accuracy of 78%, 80%, and 77% were reached using a fourfold cross-validation approach. The addition of other a-specific gas sensors, or of sensors specific to certain compounds, could improve the classification accuracy, therefore allowing for the development of a clinical tool to be integrated in the clinical pipeline for exhaled breath analysis and lung cancer early diagnosis.

scholarly journals Metabolic Signatures of Lung Cancer in Sputum and Exhaled Breath Condensate Detected by 1H Magnetic Resonance Spectroscopy: A Feasibility Study

2016 ◽  
Vol 9 ◽  
pp. MRI.S40864 ◽  
Author(s):  
Naseer Ahmed ◽  
Tedros Bezabeh ◽  
Omkar B. Ijare ◽  
Renelle Myers ◽  
Reem Alomran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Magnetic Resonance ◽  
Cancer Patients ◽  
Exhaled Breath Condensate ◽  
Resonance Spectroscopy ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Metabolic Biomarkers ◽  
Monitoring Treatment ◽  
Breath Condensate

Objectives Lung cancer is one of the most lethal cancers. Currently, there are no biomarkers for early detection, monitoring treatment response, and detecting recurrent lung cancer. We undertook this study to determine if 1H magnetic resonance spectroscopy (MRS) of sputum and exhaled breath condensate (EBC), as a noninvasive tool, can identify metabolic biomarkers of lung cancer. Materials and Methods Sputum and EBC samples were collected from 20 patients, comprising patients with pathologically confirmed non-small cell lung cancer ( n = 10) and patients with benign respiratory conditions ( n = 10). Both sputum and EBC samples were collected from 18 patients; 2 patients provided EBC samples only. 1H MR spectra were obtained on a Bruker Avance 400 MHz nuclear magnetic resonance (NMR) spectrometer. Sputum samples were further confirmed cytologically to distinguish between true sputum and saliva. Results In the EBC samples, median concentrations of propionate, ethanol, acetate, and acetone were higher in lung cancer patients compared to the patients with benign conditions. Median concentration of methanol was lower in lung cancer patients (0.028 mM) than in patients with benign conditions (0.067 mM; P = 0.028). In the combined sputum and saliva and the cytologically confirmed sputum samples, median concentrations of N-acetyl sugars, glycoprotein, propionate, lysine, acetate, and formate were lower in the lung cancer patients than in patients with benign conditions. Glucose was found to be consistently absent in the combined sputum and saliva samples (88%) as well as in the cytologically confirmed sputum samples (86%) of lung cancer patients. Conclusion Absence of glucose in sputum and lower concentrations of methanol in EBC of lung cancer patients discerned by 1H MRS may serve as metabolic biomarkers of lung cancer for early detection, monitoring treatment response, and detecting recurrence.

scholarly journals Multimodal chemometric approach for the analysis of human exhaled breath in lung cancer patients by TD-GC × GC-TOFMS

2019 ◽  
Vol 1114-1115 ◽  
pp. 146-153 ◽  
Author(s):  
R. Pesesse ◽  
P.-H. Stefanuto ◽  
F. Schleich ◽  
R. Louis ◽  
J.-F. Focant
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Chemometric Approach

Clinical significance of cytokines levels in exhaled breath condensate (EBC) and serum of lung cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22202-e22202
Author(s):  
Georgia Lamprodimou ◽  
Athanasios Athanasiadis ◽  
Theodora Kerenidi ◽  
Dimitrios Doufexis ◽  
Martha Lada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Prognostic Significance ◽  
Stage Iv ◽  
Serum Levels ◽  
Rank Test ◽  
Exhaled Breath ◽  
Lower Serum ◽  
Lung Cancer Patients

e22202 Background: Cytokines are known to play an important role in carcinogenesis.The aim of this study is to measure pre-treatment concentrations of cytokines IL6, IL10, IL1β and IL8, in EBC and serum of lung cancer patients and to assess any possible association with clinicopathological variables and survival. Methods: From February 2010 to May 2011 we enrolled 73 patients with previously untreated lung cancer, 67 males and 6 females, age 67.7±9.5 years, 46 smokers and 27 ex-smokers, and 30 healthy individuals as controls. Sixty-one patients had NSCLC and 12 SCLC (5 stage I, 3 stage II, 19 stage III and 46 stage IV). EBC was collected using the Ecoscreen device (Viasys, Germany). Serum and EBC levels of cytokines were analyzed by commercially available enzyme-immunosorbent assay kits (ELISA). Results: All cytokines but IL8 were detectable in both materials. IL8 was not detected in EBC. All cytokines were significantly increased in patients with lung cancer in comparison to controls (IL6: serum P<0.0001, EBC P=0.001; IL10: serum P= 0.006, EBC P=0.037; IL1β: serum P= 0.032, EBC P=0.005; IL8 serum P=0.001). Moreover, a statistically significant correlation was found between IL10 levels in EBC and serum (P=0.001, Rho=0.334). In EBC, higher levels of IL6 were found in patients with T3-T4 disease than in those with T1-T2 [4.27 pg/ml (2.46-5.99) vs 3.12 pg/ml (1.35-5.03), P=0.036]. Furthermore, smokers had higher serum levels of IL6 compared to ex-smokers [10.19 pg/ml (4.92-17.38) vs 4.46 pg/ml (1.88-11.53), P=0.009]. Finally, lower serum levels of IL6 < median value (9.55pg/ml) were associated with improved survival (median overall survival 338 days vs 237 days Log Rank test, P= 0.046). Conclusions: Elevated levels of measured cytokines were found in both EBC and serum of lung cancer patients. Particularly, IL6 levels were related to T-stage and smoking status, while lower serum levels of IL6 with survival. These findings suggest that cytokines should be further studied in order to evaluate their diagnostic and prognostic significance. EBC could provide a simple, noninvasive and economic method for the monitoring of biomarkers in patients with lung cancer.

Sign in / Sign up

Export Citation Format

Share Document